What is Endra Life Sciences Inc's earnings per share (EPS)?

Endra Life Sciences Inc (NDRA) reported diluted earnings per share of $-8.93 for fiscal year 2025. This represents a 84.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Endra Life Sciences Inc Financials

NDRA

Source SEC Filings (10-K/10-Q) Updated May 15, 2026 Currency USD FYE December

This page shows Endra Life Sciences Inc (NDRA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NDRA FY2025 2026-05-15

ENDRA’s cost-cutting has nearly halved annual cash burn, yet it remains an externally funded development business.

In the latest year, financing inflow of $5.7M only barely covered operating cash burn of -$5.2M. That is why cash finished at $762K and the current ratio fell to 1.3x even though the income statement looked less negative than a year earlier; the business is leaner, but not yet self-funding.

The latest improvement came from a smaller cost base, not evidence of a scaling revenue engine: SG&A dropped from $7.1M to $3.7M. R&D spending also stepped down, and operating cash flow remained close to net loss, so the narrower deficit mostly reflects real cash savings rather than accounting effects.

With $1.6M of liabilities against $2.3M of equity, the balance sheet is not dominated by debt. But liquidity is much tighter than solvency: current assets only modestly cover current liabilities, and inventory no longer provides a working-capital buffer, leaving access to fresh capital as the immediate operating constraint.

Financial Health Signals

Financial Profile 18/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Endra Life Sciences Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Endra Life Sciences Inc carries a low D/E ratio of 0.71, meaning only $0.71 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 88/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Endra Life Sciences Inc's current ratio of 1.29 is below the typical benchmark, resulting in a score of 21/100. However, the company holds substantial cash reserves (102% of current liabilities), which buffers actual liquidity risk. Large mature operators often run tight current ratios by design.

Returns

Endra Life Sciences Inc generates a -310.9% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -449.5% the prior year.

Piotroski F-Score Weak

2/9

Endra Life Sciences Inc passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.74x

For every $1 of reported earnings, Endra Life Sciences Inc generates $0.74 in operating cash flow (-$5.2M OCF vs -$7.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$5.7M

YoY+46.9%

Endra Life Sciences Inc's EBITDA was -$5.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 46.9% from the prior year.

Net Income

-$7.0M

YoY+38.9%

Endra Life Sciences Inc reported -$7.0M in net income in fiscal year 2025. This represents an increase of 38.9% from the prior year.

EPS (Diluted)

$-8.93

YoY+84.3%

Endra Life Sciences Inc earned $-8.93 per diluted share (EPS) in fiscal year 2025. This represents an increase of 84.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$5.2M

YoY+29.9%

Endra Life Sciences Inc generated -$5.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 29.9% from the prior year.

Cash & Debt

$762K

YoY-76.4%

5Y CAGR-36.2%

Endra Life Sciences Inc held $762K in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+119.1%

Endra Life Sciences Inc had 1M shares outstanding in fiscal year 2025. This represents an increase of 119.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-310.9%

YoY+138.5pp

5Y CAGR-147.4pp

Endra Life Sciences Inc's ROE was -310.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 138.5 percentage points from the prior year.

Capital Allocation

R&D Spending

$1.8M

YoY-42.0%

5Y CAGR-20.7%

Endra Life Sciences Inc invested $1.8M in research and development in fiscal year 2025. This represents a decrease of 42.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$17K

YoY+8.0%

5Y CAGR-25.5%

Endra Life Sciences Inc invested $17K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 8.0% from the prior year.

NDRA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	$0
Gross Profit	N/A	N/A	N/A	N/A	N/A	$0
R&D Expenses	$1.8M-42.0%	$3.2M-36.2%	$5.0M-23.7%	$6.6M+19.5%	$5.5M-7.4%	$5.9M
SG&A Expenses	$3.7M-47.2%	$7.1M+50.2%	$4.7M-9.2%	$5.2M+4.7%	$4.9M-1.2%	$5.0M
Operating Income	-$5.8M+46.7%	-$10.8M-2.8%	-$10.5M+20.0%	-$13.2M-14.4%	-$11.5M0.0%	-$11.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0
Net Income	-$7.0M+38.9%	-$11.5M-14.4%	-$10.1M+23.7%	-$13.2M-17.3%	-$11.2M+4.2%	-$11.7M
EPS (Diluted)	$-8.93+84.3%	$-56.94	$-2766.85	N/A	N/A	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$776K	N/A	$432K+13.4%	$381K-27.9%	$529K	N/A	$794K+10.9%	$716K
SG&A Expenses	$1.4M	N/A	$893K+4.9%	$851K-2.3%	$872K	N/A	$631K-53.3%	$1.4M
Operating Income	-$2.2M	N/A	-$1.4M-5.4%	-$1.3M+11.4%	-$1.5M	N/A	-$1.5M+32.4%	-$2.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	$0	$0	N/A	$0	$0
Net Income	-$1.3M	N/A	-$1.6M-30.2%	-$1.2M-18.3%	-$1.0M	N/A	-$2.4M-5.6%	-$2.2M
EPS (Diluted)	$-1.09	N/A	$-2.10	N/A	N/A	N/A	$-9.54	N/A

NDRA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$3.9M-13.4%	$4.5M-34.1%	$6.8M-27.2%	$9.3M-28.0%	$12.9M+46.9%	$8.8M
Current Assets	$968K-71.8%	$3.4M+13.2%	$3.0M-43.6%	$5.4M-55.5%	$12.1M+47.4%	$8.2M
Cash & Equivalents	$762K-76.4%	$3.2M+14.0%	$2.8M-42.0%	$4.9M-48.3%	$9.5M+30.9%	$7.2M
Inventory	$0	$0-100.0%	$2.6M-0.8%	$2.6M+105.9%	$1.3M+117.9%	$590K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$1.6M-15.8%	$1.9M+72.8%	$1.1M-47.1%	$2.1M-1.0%	$2.1M+31.0%	$1.6M
Current Liabilities	$751K+24.1%	$605K-33.0%	$903K-47.0%	$1.7M+10.4%	$1.5M+56.5%	$987K
Long-Term Debt	N/A	$0	$0	$0-100.0%	$547K	N/A
Total Equity	$2.3M-11.7%	$2.6M-54.8%	$5.7M-21.5%	$7.2M-33.2%	$10.8M+50.4%	$7.2M
Retained Earnings	-$110.5M-6.8%	-$103.4M-12.5%	-$91.9M-12.3%	-$81.9M-19.2%	-$68.7M-19.8%	-$57.3M

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	N/A	$3.9M+96.2%	$2.0M-30.0%	$2.8M-11.4%	$3.2M-28.8%	$4.5M-46.9%	$8.4M-19.8%	$10.4M
Current Assets	N/A	$968K-7.7%	$1.0M-43.4%	$1.9M-15.0%	$2.2M-36.5%	$3.4M-30.8%	$5.0M-26.1%	$6.7M
Cash & Equivalents	N/A	$762K-4.0%	$794K-56.1%	$1.8M-12.4%	$2.1M-36.1%	$3.2M-31.9%	$4.7M-25.9%	$6.4M
Inventory	N/A	$0	$0	$0	$0	$0-100.0%	$2.7M0.0%	$2.7M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	N/A	$1.6M-11.1%	$1.8M+34.3%	$1.3M-5.9%	$1.4M-25.1%	$1.9M+6.6%	$1.8M+22.5%	$1.4M
Current Liabilities	N/A	$751K-6.2%	$800K+38.8%	$577K+1.9%	$566K-6.5%	$605K-25.7%	$814K-39.7%	$1.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$0	N/A	N/A
Total Equity	N/A	$2.3M+1218.8%	$171K-88.4%	$1.5M-16.0%	$1.8M-31.5%	$2.6M-61.2%	$6.6M-26.6%	$9.0M
Retained Earnings	N/A	-$110.5M-3.0%	-$107.3M-1.5%	-$105.7M-1.2%	-$104.5M-1.0%	-$103.4M-4.2%	-$99.3M-2.4%	-$96.9M

NDRA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$5.2M+30.0%	-$7.4M+22.5%	-$9.5M+25.2%	-$12.8M-14.8%	-$11.1M-3.5%	-$10.7M
Capital Expenditures	$17K+8.0%	$16K-52.8%	$34K-83.3%	$203K+350.2%	$45K-40.3%	$75K
Free Cash Flow	-$5.2M+29.9%	-$7.4M+22.6%	-$9.6M+26.1%	-$13.0M-16.2%	-$11.2M-3.2%	-$10.8M
Investing Cash Flow	-$3.0M-23479.9%	-$13K+48.2%	-$25K+87.8%	-$203K-350.2%	-$45K+40.3%	-$75K
Financing Cash Flow	$5.7M-26.6%	$7.8M+3.9%	$7.5M-10.5%	$8.4M-37.3%	$13.4M+12.9%	$11.9M
Dividends Paid	N/A	N/A	N/A	$0-100.0%	$121K-69.4%	$396K
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$1.1M+30.5%	-$1.6M-38.5%	-$1.2M-4.5%	-$1.1M+13.9%	-$1.3M+14.7%	-$1.5M+8.5%	-$1.7M+20.5%	-$2.1M
Capital Expenditures	$17K	$0	$0	$0-100.0%	$17K	$0	$0+100.0%	-$11K
Free Cash Flow	-$1.1M+29.5%	-$1.6M-38.5%	-$1.2M-4.5%	-$1.1M+15.0%	-$1.3M+13.5%	-$1.5M+8.5%	-$1.7M+20.9%	-$2.1M
Investing Cash Flow	$450K+115.0%	-$3.0M	$0	$0+100.0%	-$17K	$0	$0-100.0%	$11K
Financing Cash Flow	$264K-94.2%	$4.6M+2964.3%	$149K-82.6%	$857K+488.1%	$146K	$0-100.0%	$2K-100.0%	$7.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NDRA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-310.9%+138.5pp	-449.5%-271.7pp	-177.8%+5.2pp	-182.9%-78.8pp	-104.1%+59.4pp	-163.5%
Return on Assets	-182.3%+76.1pp	-258.5%-109.5pp	-149.0%-6.8pp	-142.1%-54.9pp	-87.2%+46.5pp	-133.8%
Current Ratio	1.29-4.4	5.67+2.3	3.36+0.2	3.16-4.7	7.83-0.5	8.32
Debt-to-Equity	0.71+0.7	0.000.0	0.000.0	0.00-0.1	0.05-0.2	0.22
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	-931.2%-848.0pp	-83.2%-24.1pp	-59.1%	N/A	-35.6%-10.8pp	-24.8%
Return on Assets	N/A	N/A	-81.3%-37.6pp	-43.7%-11.0pp	-32.7%	N/A	-28.1%-6.7pp	-21.3%
Current Ratio	N/A	1.29-0.0	1.31-1.9	3.21-0.6	3.85-1.8	5.67-0.4	6.10+1.1	4.97
Debt-to-Equity	N/A	0.71-9.8	10.46+9.6	0.91+0.1	0.81+0.8	0.00-0.3	0.27+0.1	0.16
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Check Cap CHEK

$9.4M

Applied Dna Scie APDN

$7.3M

bioAffinity Tech BIAF

$7.5M

Mainz Biomed NV MYNZ

$10.6M

XWELL Inc XWEL

$11.6M

Frequently Asked Questions

Is Endra Life Sciences Inc profitable?

No, Endra Life Sciences Inc (NDRA) reported a net income of -$7.0M in fiscal year 2025.

What is Endra Life Sciences Inc's EBITDA?

Endra Life Sciences Inc (NDRA) had EBITDA of -$5.7M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Endra Life Sciences Inc's return on equity (ROE)?

Endra Life Sciences Inc (NDRA) has a return on equity of -310.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Endra Life Sciences Inc's free cash flow?

Endra Life Sciences Inc (NDRA) generated -$5.2M in free cash flow during fiscal year 2025. This represents a 29.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Endra Life Sciences Inc's operating cash flow?

Endra Life Sciences Inc (NDRA) generated -$5.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Endra Life Sciences Inc's total assets?

Endra Life Sciences Inc (NDRA) had $3.9M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Endra Life Sciences Inc's capital expenditures?

Endra Life Sciences Inc (NDRA) invested $17K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Endra Life Sciences Inc spend on research and development?

Endra Life Sciences Inc (NDRA) invested $1.8M in research and development during fiscal year 2025.

How many shares does Endra Life Sciences Inc have outstanding?

Endra Life Sciences Inc (NDRA) had 1M shares outstanding as of fiscal year 2025.

What is Endra Life Sciences Inc's current ratio?

Endra Life Sciences Inc (NDRA) had a current ratio of 1.29 as of fiscal year 2025, which is considered adequate.

What is Endra Life Sciences Inc's debt-to-equity ratio?

Endra Life Sciences Inc (NDRA) had a debt-to-equity ratio of 0.71 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Endra Life Sciences Inc's return on assets (ROA)?

Endra Life Sciences Inc (NDRA) had a return on assets of -182.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Endra Life Sciences Inc's cash runway?

Based on fiscal year 2025 data, Endra Life Sciences Inc (NDRA) had $762K in cash against an annual operating cash burn of $5.2M. This gives an estimated cash runway of approximately 2 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Endra Life Sciences Inc's Piotroski F-Score?

Endra Life Sciences Inc (NDRA) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Endra Life Sciences Inc's earnings high quality?

Endra Life Sciences Inc (NDRA) has an earnings quality ratio of 0.74x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Endra Life Sciences Inc?

Endra Life Sciences Inc (NDRA) scores 18 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.